CN114028531B - 一种治疗乳腺癌的药物及其制备方法和应用 - Google Patents
一种治疗乳腺癌的药物及其制备方法和应用 Download PDFInfo
- Publication number
- CN114028531B CN114028531B CN202111570634.7A CN202111570634A CN114028531B CN 114028531 B CN114028531 B CN 114028531B CN 202111570634 A CN202111570634 A CN 202111570634A CN 114028531 B CN114028531 B CN 114028531B
- Authority
- CN
- China
- Prior art keywords
- parts
- breast cancer
- volatile oil
- extracting
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 80
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 60
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 60
- 229940079593 drug Drugs 0.000 title abstract description 30
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 241000405414 Rehmannia Species 0.000 claims abstract description 26
- 238000011282 treatment Methods 0.000 claims abstract description 25
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 13
- 241000218671 Ephedra Species 0.000 claims abstract description 13
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 13
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 11
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 11
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 11
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 11
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 11
- 235000008397 ginger Nutrition 0.000 claims abstract description 11
- 235000006463 Brassica alba Nutrition 0.000 claims abstract description 10
- 244000140786 Brassica hirta Species 0.000 claims abstract description 10
- 235000011371 Brassica hirta Nutrition 0.000 claims abstract description 10
- 241000131329 Carabidae Species 0.000 claims abstract description 10
- 240000000233 Melia azedarach Species 0.000 claims abstract description 10
- 244000178320 Vaccaria pyramidata Species 0.000 claims abstract description 10
- 235000010587 Vaccaria pyramidata Nutrition 0.000 claims abstract description 10
- 210000003056 antler Anatomy 0.000 claims abstract description 10
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 10
- 235000011477 liquorice Nutrition 0.000 claims abstract description 10
- 240000001949 Taraxacum officinale Species 0.000 claims abstract 2
- 244000273928 Zingiber officinale Species 0.000 claims abstract 2
- 239000000341 volatile oil Substances 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 238000002156 mixing Methods 0.000 claims description 30
- 238000004821 distillation Methods 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 230000002829 reductive effect Effects 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 241000222640 Polyporus Species 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 235000017276 Salvia Nutrition 0.000 claims description 8
- 241000220261 Sinapis Species 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 238000005507 spraying Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 3
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 241001489978 Eupolyphaga Species 0.000 claims description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 229960001462 sodium cyclamate Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 27
- 210000004369 blood Anatomy 0.000 abstract description 17
- 239000008280 blood Substances 0.000 abstract description 17
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 12
- 208000026435 phlegm Diseases 0.000 abstract description 12
- 208000024891 symptom Diseases 0.000 abstract description 10
- 201000011510 cancer Diseases 0.000 abstract description 8
- 238000001959 radiotherapy Methods 0.000 abstract description 7
- 238000002512 chemotherapy Methods 0.000 abstract description 6
- 230000012010 growth Effects 0.000 abstract description 6
- 239000002994 raw material Substances 0.000 abstract description 5
- 244000171085 Polyporus umbellatus Species 0.000 abstract description 3
- 235000004837 Polyporus umbellatus Nutrition 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 235000005412 red sage Nutrition 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- 230000004083 survival effect Effects 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- 229940044683 chemotherapy drug Drugs 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000036737 immune function Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 41
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 15
- 238000000684 flow cytometry Methods 0.000 description 13
- 238000005406 washing Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 10
- 241000245665 Taraxacum Species 0.000 description 9
- 241000234314 Zingiber Species 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 238000010792 warming Methods 0.000 description 8
- 230000003213 activating effect Effects 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000003053 toxin Substances 0.000 description 7
- 231100000765 toxin Toxicity 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002791 soaking Methods 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 206010006272 Breast mass Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000002445 nipple Anatomy 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 206010006223 Breast discharge Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010040925 Skin striae Diseases 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- NTDFJPCHHGBHCO-UHFFFAOYSA-N 7,9-dihydro-3H-purine-2,6,8-trione Chemical compound OC1=NC(O)=C2NC(O)=NC2=N1.N1C(=O)NC(=O)C2=C1NC(=O)N2 NTDFJPCHHGBHCO-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241001465251 Ephedra sinica Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Insects & Arthropods (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Animal Husbandry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及抗肿瘤药物领域，公开了一种治疗乳腺癌的药物，所述药物由以下重量份的原料药制备而成：地黄5～16份、熟地黄5～12份、肉桂2～6份、麻黄2～6份、鹿角片6～18份、白芥子3～9份、猪苓2～9份、蒲公英9～20份、橘叶2～9份、川楝子2～9份、土鳖虫2～9份、王不留行2～9份、丹参3～9份、炮姜2～6份、甘草2～9份。本发明中药复方组合物体现了以扶正固本为主,兼以祛瘀解毒化痰的治疗理念，在抑制乳腺癌细胞增长的同时可以提高乳腺癌患者的免疫功能，减轻放化疗产生的副作用，增强癌细胞对化疗药物的敏感性，改善患者的临床症状，提高生存质量，是一种配伍严密、疗效确切、服用方便的抗乳腺癌现代制剂。
Description
技术领域
本发明涉及抗肿瘤药物领域，更具体地涉及一种治疗乳腺癌的药物及其制备方法和应用。
背景技术
根据2020年美国癌症协会发布的数据表明，乳腺癌已成为全球总人口癌症发病率排行第二的恶性肿瘤，是我国女性最常见的恶性肿瘤，全球乳腺癌新发病例高达226万，每年发病人数约为30.4万。2000～2020年，我国乳腺癌的发病率和死亡率分别以4.1％和1.5％的增长率发生变化，并且呈现出持续增高的整体发展趋势，严重威胁我国女性身心健康。虽然手术、放化疗、内分泌治疗及靶向治疗等多种手段结合应用于乳腺癌的综合治疗，但这些治疗方法引起的恶心、呕吐、白细胞减低、肝肾功损伤等不良反应及并发症严重影响患者的生存质量与期限，且费用高昂。特别是三阴性乳腺癌恶性程度高、侵袭性强，转移率高，治疗以放化疗为主，患者对内分泌治疗与靶向治疗不敏感，多丧失手术机会。因此，提高乳腺癌患者生存质量，延长患者寿命，增强患者免疫力，降低放化疗药物的毒副作用等是治疗乳腺癌患者急需解决的关键问题。
中医治疗肿瘤虽很难直接把肿瘤即刻消除，但它可能改变肿瘤的生长环境，抑制生长进程，减少癌症的复发转移；调节机体免疫力，增加放化疗敏感性，缓解其毒副反应，在提高患者生活质量方面具有显著优势；而对那些不适于手术只能进行放化疗及其他治疗的患者，更是提供了一种较好的治疗策略。
发明内容
为解决现有技术中乳腺癌的治疗副作用大，病人生存率低等问题，本发明提供一种治疗乳腺癌的药物及其制备方法和应用。
本发明采用的具体方案为：一种治疗乳腺癌的药物，所述药物由以下重量份的原料药制备而成：地黄6～16份、熟地黄6～12份、肉桂3～6份、麻黄3～6份、鹿角片9～18份、白芥子3～9份、猪苓3～9份、蒲公英9～20份、橘叶2～9份、川楝子2～9份、土鳖虫2～9份、王不留行2～9份、丹参3～9份、炮姜2～6份、甘草3～9份。
所述药物由以下重量份的原料药制备而成：地黄6～12份、熟地黄6～9份、肉桂3～5份、麻黄3～4份、鹿角片9～15份、白芥子3～8份、猪苓3～7份、蒲公英9～15份、橘叶3～6份、川楝子3～6份、土鳖虫2～5份、王不留行3～6份、丹参3～6份、炮姜2～4份、甘草3～5份。
所述药物由以下重量份的原料药制备而成：地黄12份、熟地黄9份、肉桂3份、麻黄3份、鹿角片15份、白芥子5份、猪苓5份、蒲公英12份、橘叶5份、川楝子3份、土鳖虫3份、王不留行3份、丹参5份、炮姜3份、甘草3份。
另一方面，本发明提供一种治疗乳腺癌的药物的制备方法，所述方法包括如下步骤：
(1)用蒸馏法提取挥发油，取白芥子、麻黄、炮姜及肉桂采用蒸馏法提取挥发油；蒸馏后的水溶液，滤过，备用；
(2)将地黄、熟地黄、鹿角片、猪苓、蒲公英、橘叶、川楝子、土鳖虫、王不留行、丹参、炮姜、甘草混合加水煎煮，将煎液过滤后，得到滤液；
(3)将滤液浓缩得清膏，减压干燥、粉碎成细粉；
(4)加入药物辅料，干燥，喷入步骤(1)得到的挥发油，混匀，得到所述药物。
所述步骤(1)中蒸馏法提取挥发油的时间为2～8小时。
所述步骤(1)得到挥发油后，用无水乙醇冲洗步骤(1)提取挥发油用到的挥发油提取器，冲洗液一同并入挥发油中。
所述步骤(1)用乙醚提取挥发油。
所述步骤(2)煎煮的具体方法为，加水煎煮1～3次，第一次加8～12倍量水，浸泡0.3～1.5h，提取1～1.5h；第二次加6～10倍量水，提取1～1.5h，合并煎液，滤过，滤液与上述(1)蒸馏后的水溶液合并。
所述步骤(3)中浓缩至相对密度为1.10～1.30的清膏，常压或减压干燥，粉碎成细粉。
加入药物辅料将所述药物制备成颗粒剂、片剂、胶囊、丸剂或煎膏剂。
本发明相对于现有技术具有如下有益效果：
1.本发明依据中医药理论，以扶正固本为主，兼以祛瘀解毒化痰，对乳腺癌进行辩证施治，提供一种由12种原料药组成的药物，具有温经通阳、活血行气、清热解毒、化痰散结功效，用于正虚邪恋、癌毒瘀阻证候。结合临床二十余年治疗乳腺癌患者经验及证治规律总结，乳腺癌由脏腑功能失调，气血津液运行失常，继发气滞、血瘀、痰浊、癌毒，相互搏结，渐积而成，由阳虚寒凝至痰瘀互结至痰毒﹑瘀毒化热，其治疗贵在“通”、“消”，从而形成了本发明温经通阳、活血行气、清热解毒、化痰散结的中药复方组合物。
2.本发明所述的制备方法简便易行，最大程度的保留了药物的有效成分，药物有效成分损失减少，适于工业化生产。
3.本发明所述药物添加药物辅料后可以制成颗粒剂、片剂、胶囊、丸剂或煎膏剂多种剂型，满足不同患者需求，便于患者服用。本发明所述的药物的制备方法有效成分含量高、杂质少，能够迅速发挥药效，适合工业化生产。
4.本发明所述药物适用于治疗乳腺癌的全过程，包括术前、术后放、化疗期间，有助于提高病人的机体免疫力，对防止乳腺癌复发，延长患者的生存时间具有重要作用。
附图说明
图1为实施例5中不同浓度的大鼠颗粒药血清在不同时间对4T1细胞的抑制作用；
图2为实施例5中各组实验鼠的肿瘤体积随时间生长的曲线；
图3为实施例5中各组实验鼠肝脏功能的变化；
图4为实施例5中各组实验鼠肾脏功能的变化；
图5为实施例5中颗粒组中小鼠脾脏中T细胞流式细胞图；
图6为实施例5中模型组中小鼠脾脏中T细胞流式细胞图；
图7为实施例5中环磷酰胺组中小鼠脾脏中T细胞流式细胞图；
图8为实施例5中联合组中小鼠脾脏中B细胞流式细胞图；
图9为实施例5中颗粒组中小鼠脾脏中B细胞流式细胞图；
图10为实施例5中模型组中小鼠脾脏中B细胞流式细胞图；
图11为实施例5中环磷酰胺组中小鼠脾脏中B细胞流式细胞图；
图12为实施例5中联合组中小鼠脾脏中B细胞流式细胞图；
图13为实施例5中颗粒组中小鼠脾脏中MDSCs细胞流式细胞图；
图14为实施例5中模型组中小鼠脾脏中MDSCs细胞流式细胞图；
图15为实施例5中环磷酰胺组中小鼠脾脏中MDSCs细胞流式细胞图；
图16为实施例5中联合组中小鼠脾脏中MDSCs细胞流式细胞图。
具体实施方式
在下文将结合附图对本发明做进一步详细地说明，显然此处应该理解的是，所描述的实施方案不是全部的实施方案，仅用于解释说明本发明，而不限制本发明。
实施例1
一种治疗乳腺癌的药物，地黄16g、熟地黄12g、肉桂6g、麻黄6g、鹿角片18g、白芥子9g、猪苓9g、蒲公英20g、橘叶9g、川楝子9g、土鳖虫9g、王不留行9g、丹参9g、炮姜6g、甘草9g。
上述药物的制备方法为：用蒸馏法提取挥发油，取白芥子、麻黄、炮姜及肉桂采用蒸馏法提取挥发油；蒸馏法提取挥发油的时间为8小时，用无水乙醇冲洗提取挥发油用到的挥发油提取器，冲洗液一同并入挥发油中；将地黄等十一味药加水煎煮三次，第一次加12倍量水，浸泡1.5h，提取1.5h；第二次加10倍量水，提取1.5h，第三次加10倍水，提取1.5h，合并煎液，滤过，滤液与上述水溶液合并，浓缩至相对密度为1.30(80℃)的清膏，减压干燥，粉碎成细粉，加入辅料，制粒，干燥，整粒，喷入上述挥发油，混匀，将上述药物制成片剂。
实施例2
一种治疗乳腺癌的药物，地黄12g、熟地黄9g、肉桂5g、麻黄4g、鹿角片15g、白芥子8g、猪苓7g、蒲公英15g、橘叶5g、川楝子6g、土鳖虫5g、王不留行6g、丹参5g、炮姜3g、甘草5g。
上述药物的制备方法为：用蒸馏法提取挥发油，取白芥子、麻黄、炮姜及肉桂采用蒸馏法提取挥发油；蒸馏法提取挥发油的时间为6小时，用无水乙醇冲洗提取挥发油用到的挥发油提取器，冲洗液一同并入挥发油中；将地黄等十一味药加水煎煮两次，第一次加10倍量水，浸泡1h，提取1.2h；第二次加8倍量水，提取1.2h，合并煎液，滤过，滤液与上述水溶液合并，浓缩至相对密度为1.20(80℃)的清膏，减压干燥，粉碎成细粉，加入辅料，制粒，干燥，整粒，喷入上述挥发油，混匀，将上述药物制成胶囊。
实施例3
一种治疗乳腺癌的药物，地黄12g、熟地黄9g、肉桂3g、麻黄3g、鹿角片10g、白芥子5g、猪苓5g、蒲公英12g、橘叶5g、川楝子3g、土鳖虫3g、王不留行3g、丹参5g、炮姜3g、甘草3g。
上述药物的制备方法为：用蒸馏法提取挥发油，取白芥子、麻黄、炮姜及肉桂采用蒸馏法提取挥发油；蒸馏法提取挥发油的时间为4小时；用无水乙醇冲洗提取挥发油用到的挥发油提取器，冲洗液一同并入挥发油中；将地黄等十一味药加水煎煮两次，第一次加9倍量水，浸泡0.5h，提取1.3h；第二次加9倍量水，提取1.3h，合并煎液，滤过，滤液与上述水溶液合并，浓缩至相对密度为1.20(80℃)的清膏，减压干燥，粉碎成细粉，喷入上述挥发油，加入辅料，混合，将上述药物制成丸剂。
实施例4
一种治疗乳腺癌的药物，地黄9g、熟地黄9g、肉桂3g、麻黄3g、鹿角片15g、白芥子5g、猪苓3g、蒲公英15g、橘叶5g、川楝子3g、土鳖虫3g、王不留行5g、丹参5g、炮姜3g、甘草3g。
上述药物的制备方法为：用蒸馏法提取挥发油，取白芥子、麻黄、炮姜及肉桂采用蒸馏法提取挥发油；蒸馏法提取挥发油的时间为4小时；用无水乙醇冲洗提取挥发油用到的挥发油提取器，冲洗液一同并入挥发油中；将地黄等十一味药加水煎煮两次，第一次加9倍量水，浸泡0.5h，提取1.3h；第二次加7倍量水，提取1.3h，合并煎液，滤过，滤液与上述水溶液合并，浓缩至相对密度为1.20(80℃)的清膏，加入挥发油和辅料，混匀，将上述药物制成煎膏剂。
实施例5
一种治疗乳腺癌的药物，由地黄9g、熟地黄6g、肉桂3g、麻黄3g、鹿角片9g、白芥子3g、猪苓3g、蒲公英9g、橘叶2g、川楝子2g、土鳖虫3g、王不留行2g、丹参3g、炮姜2g、甘草3g。
上述药物的制备方法为：用蒸馏法提取挥发油，取白芥子、麻黄、炮姜及肉桂采用蒸馏法提取挥发油；蒸馏法提取挥发油的时间为2小时，用无水乙醇冲洗提取挥发油用到的挥发油提取器，冲洗液一同并入挥发油中；将地黄等十一味药加水煎煮两次，第一次加8倍量水，浸泡0.3h，提取1h；第二次加6倍量水，提取1h，合并煎液，滤过，滤液与上述水溶液合并，浓缩至相对密度为1.10(80℃)的清膏，减压干燥，粉碎成细粉，加入甜蜜素、糊精混合，85％乙醇制粒，干燥，整粒，喷入上述挥发油，混匀，将上述药物制成颗粒剂。
分别对实施例1～5做如下实验，最佳实施例为实施例5，对实施例5的实验结果作如下说明：
实施例5制备得到的药物的对4T1小鼠乳腺癌细胞的增殖有抑制作用：
用不同浓度的实施例5制备得到的药物颗粒大鼠含药血清干预对数生长期的4T1细胞，MTT法于不同时间点观察各实验组细胞的抑制情况，参见附图1，结果表明各浓度含药血清作用于4T1细胞24小时均表现出了不同程度的抑制细胞增殖的作用，30％浓度的抑制率最佳。
实施例5制备得到的药物的对4T1小鼠乳腺癌细胞移植瘤增长的影响：
实验选用BALB/c雌性小鼠56只，4～5周龄，体重20g±2g，适应性喂养一周后，进行水合氯醛麻醉，所有小鼠均于右侧倒数第2对乳腺脂肪垫部位剃毛并消毒，阴性组10只注射无血清培养基，其余小鼠皮下接种4T1细胞悬液(浓度为1×106/m L)，每只注射100μL细胞悬液，制备4T1乳腺癌移植瘤模型。将造模成功的移植瘤模型小鼠随机分为模型组、环磷酰胺组、颗粒组、环磷酰胺联合颗粒组(以下称为联合组)，一共4组，每组12只。环磷酰胺组按环磷酰胺100mg/kg剂量腹腔注射0.1ml，每周一次颗粒组给予实施例5中的药物颗粒每天5.2g/kg、0.2ml/10g灌胃，每天一次；联合组每天按照5.2g/kg、0.2ml/10g的剂量给予实施例5中的药物进行灌胃的同时腹腔注射0.1ml的100mg/kg环磷酰胺，每周一次；模型组小鼠给与同等体积的蒸馏水灌胃；阴性组小鼠用于排除环境、饮食或肿瘤细胞外物质致癌的影响，给与0.2ml/10g的蒸馏水灌胃干预。4T1小鼠乳腺癌细胞移植瘤模型开始给药干预后，每3天测量一次肿瘤大小，绘制时间瘤体生长曲线，如图2，给药21天结束后，剥离瘤体称重，计算各组抑瘤率，见表1。
表1.不同实验组对4T1小鼠乳腺癌细胞移植瘤的抑制率(n＝8)
注：和模型组对照组比较*P＜0.05，**P＜0.01；和环磷酰胺组比较#P＜0.05，##P＜0.01
结果显示，各组小鼠瘤体随着时间的延长不同程度的增大，颗粒组、环磷酰胺组和联合组肿瘤体积增长的程度均明显低于模型组，有显著差异(P＜0.01)。
实施例5制备得到的药物对4T1小鼠乳腺癌细胞移植瘤模型血液学的影响：
药物干预周期结束时，将麻醉的乳腺癌小鼠眼球取血行一般血细胞分析及肝功能和肾功能的检测，观察各实验组小鼠白细胞、白细胞分类以及血小板(见表2)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)(如图3)、尿素氮(BUN)、尿酸(URIC)(如图4)的变化。
表2.不同实验组血细胞分析结果的比较(n＝6)
注：表格中空位表示未测出数值，由于白细胞数量过高仪器无法分类造成；**为和模型对照组白细胞计数比较有统计学意义，**P＜0.01；##为和环磷酰胺组比较白细胞计数有统计学意义，#P＜0.01。
结果显示，颗粒组小鼠比模型组小鼠的白细胞计数趋于正常参考范围，联合用药可以帮助乳腺癌小鼠的白细胞计数几乎趋于正常。
附图3，结果表明，各实验组小鼠肝功中的ALT均在参考区间内，但是环磷酰胺组的AST超出了参考范围，说明实验周期内环磷酰胺已经对小鼠的肝脏产生了毒副作用，而联合用药组降低了这种毒副作用。
附图4，结果表明，各实验组小鼠肾功中的两个指标均在参考区间内，但是在实验周期内环磷酰胺组小鼠的尿素氮结果已经显示出了增高趋势。
实施例5制备得到的药物对4T1小鼠乳腺癌细胞移植瘤模型炎性细胞因子的影响：
药物干预周期结束时，将麻醉的乳腺癌小鼠眼球取血行血清的ELISA实验，检测IL-6、IL-10、IFN-γ细胞因子，观察药物对各炎症因子影响，见表3。
表3.不同实验组血清细胞因子的结果比较(n＝6)
注：和模型组比较*P＜0.05，**P＜0.01
结果表明，颗粒组和联合组均可增加乳腺癌小鼠血清中抗炎因子IL-10、IFN-γ的含量，降低促炎因子IL-6的含量，改善了乳腺癌小鼠的炎症微环境。
实施例5对4T1小鼠乳腺癌细胞移植瘤模型肿瘤微环境免疫细胞影响：
药物干预周期结束时，摘取麻醉的乳腺癌小鼠新鲜脾脏，制备脾细胞单悬液行流式细胞术检测各实验组小鼠脾脏的T细胞、B细胞及MDSCs细胞，观察药物对各实验组小鼠免疫细胞的影响，如图5、6、7、8和见表4。
表4.不同实验组流式细胞分析结果的比较(n＝5)
注：和模型组对照组比较*P＜0.05，**P＜0.01；和环磷酰胺组比较#P＜0.05，##P＜0.01
结果表明，与模型组比较，颗粒组、联合组不同程度的提高了实验组小鼠脾脏的T、B细胞含量，降低了MDSCs细胞的含量，提高了乳腺癌小鼠的免疫功能。环磷酰胺组虽然降低了MDSCs细胞含量，但是亦减低了T、B细胞的含量。
为临床病历1～6，提供本发明实施例5所述药物：
病例1：患者，女，34岁，经医院确诊为乳腺癌。症见左侧乳房肿块，质硬，掣痛。服用37剂本发明的中药方加减治疗后，肿块减小，变软，疼痛消失。
病例2：患者，女，76岁，经医院确诊为乳腺癌。症见左乳腺肿块，质硬，隐痛。服用63剂本发明的中药方加减治疗后，乳腺隐痛大减，肿块减小。
病例3：患者，女，36岁，经医院确诊为乳腺癌。症见双侧乳头溢液，呈稀淡白色，乳房时有胀痛感，可触及硬结，服用35剂本发明的中药方加减治疗后，患者一般情况良好，无明显不适感，乳头未发现溢液。
病例4：患者，女，43岁。经医院确诊为乳腺癌。症见左侧乳房肿块，质硬，压之疼痛，左乳头凹陷，挤压左乳头可见清水样溢液。服用30剂本发明的中药方加减治疗后，诸症均有好转。
病例5：患者，女，59岁。经医院确诊为乳腺癌。行右乳改良根治术后症见右上肢水肿，外展受限，活动则痛。服用60余剂本发明的中药方加减治疗后，水肿明显好转，疼痛亦明显减轻。
病例6：患者，女，48岁。经医院确诊为乳腺癌。行左乳癌根治术后，症见左上肢及手背处肿胀明显，皮色发亮，压之有凹陷，旋即复肿。晨起略减，下午渐重，晚上尤甚。服用本发明的中药方加减治疗3个月后，左上肢水肿明显消退。
本发明中，所述药物中以生地凉血养阴、生津，熟地黄滋补阴血、填精益髓，鹿角片味咸性温、温通入血，温肾阳、行血消肿为君药；辅以肉桂麻黄共为臣药。肉桂入血分温通血脉，有补火助阳，引火归源之效，且作用温和持久；麻黄用量较少，通阳散寒开腠理，使阳气迅速的布达周身，与肉桂收散相合，通补兼顾，共奏奇效。佐以炮姜温中散寒，温经通脉以消除寒凝之气。三药配伍既可温经散寒，通阳散结解寒凝，又可引熟地、鹿角片直达病所。白芥子辛温，走蹿经络，通阳散滞而消痰结，可祛皮里膜外之痰；猪苓甘淡平，利水渗湿而不伤阴，襄助其化痰散结之力；橘叶味苦辛性平，入足厥阴肝经气分，舒肝解郁，行气散结，消肿散毒；川楝子味苦性寒，舒肝泻热、行气止痛；蒲公英味苦甘寒，清热解毒，消肿散结；土鳖虫咸寒破瘀血，续筋骨；王不留行活血化瘀，通乳消肿；丹参活血祛瘀，凉血消肿；使以生甘草，解毒和诸药。
全方用药精巧，配伍严密，诸药合用使经络通，寒凝解，气血行，癌毒散。功能主治明确，临床疗效肯定。根据古代医家对乳腺癌的认识，结合临床二十余年对乳腺癌患者治疗经验及证治规律总结，按照中医学“补虚祛实、通经和络”理论立法，以温经通阳、活血行气、清热解毒、化痰散结治则组方，按照中药的“升降浮沉”理论，将补阴药与补阳药并用，温通之品与辛散药相伍，注重“通”、“消”大则，体现了扶正固本为主，兼以祛瘀解毒化痰的治疗理念，有别于当代医生普遍采用的清热解毒之法。立法组方上独特精炼、新颖明确，针对乳腺癌虚瘀痰毒凝结的病理特征，制定治法方药，体现了乳腺癌治疗中“病证结合”的原则。本方可抑制乳房肿块的增长，改善临床症状，增强机体的免疫力，减少放化疗的副作用，提高患者生活质量，是一种配伍严密、疗效确切、服用方便的抗乳腺癌现代制剂。
以上附图及解释说明仅为本发明的一种具体实施方式，但本发明的具体保护范围不仅限以上解释说明，任何在本发明揭露的技术思路范围内，及根据本发明的技术方案加以简单地替换或改变，都应在本发明的保护范围之内。
Claims (7)
1.一种治疗乳腺癌的药物，其特征在于，所述药物由地黄9g、熟地黄6g、肉桂3g、麻黄3g、鹿角片9g、白芥子3g、猪苓3g、蒲公英9g、橘叶2g、川楝子2g、土鳖虫3g、王不留行2g、丹参3g、炮姜2g、甘草3g制成。
2.一种如权利要求1所述的治疗乳腺癌的药物的制备方法，其特征在于，所述方法包括如下步骤：
（1）用蒸馏法提取挥发油，取白芥子、麻黄、炮姜及肉桂采用蒸馏法提取挥发油；
（2）将地黄、熟地黄、鹿角片、猪苓、蒲公英、橘叶、川楝子、土鳖虫、王不留行、丹参、炮姜、甘草混合后加水煎煮，将煎液过滤后，得到滤液；
（3）将滤液浓缩得清膏，减压干燥、粉碎成细粉；
（4）加入药物辅料，干燥，喷入步骤（1）得到的挥发油，混匀，得到所述药物。
3.根据权利要求2所述的治疗乳腺癌的药物的制备方法，其特征在于，所述步骤（1）中蒸馏法提取挥发油的时间为2小时。
4.根据权利要求2所述的治疗乳腺癌的药物的制备方法，其特征在于，所述步骤（1）得到挥发油后，用无水乙醇冲洗步骤（1）提取挥发油用到的挥发油提取器，冲洗液一同并入挥发油中。
5.根据权利要求2所述的治疗乳腺癌的药物的制备方法，其特征在于，所述步骤（2）煎煮的具体方法为，加水煎煮两次，第一次加8倍量水，浸泡0.3h，提取1h；第二次加6倍量水，提取1h，合并煎液，滤过，滤液与上述水溶液合并。
6.根据权利要求2所述的治疗乳腺癌的药物的制备方法，其特征在于，所述步骤（3）中浓缩至相对密度为80℃下1.1的清膏。
7.根据权利要求2所述的治疗乳腺癌的药物的制备方法，其特征在于，所述步骤（4）中的药物辅料为甜蜜素、糊精。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111570634.7A CN114028531B (zh) | 2021-12-21 | 2021-12-21 | 一种治疗乳腺癌的药物及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111570634.7A CN114028531B (zh) | 2021-12-21 | 2021-12-21 | 一种治疗乳腺癌的药物及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114028531A CN114028531A (zh) | 2022-02-11 |
| CN114028531B true CN114028531B (zh) | 2023-06-02 |
Family
ID=80140964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111570634.7A Active CN114028531B (zh) | 2021-12-21 | 2021-12-21 | 一种治疗乳腺癌的药物及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114028531B (zh) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101537153A (zh) * | 2008-03-21 | 2009-09-23 | 北京汉潮联创中药科技有限公司 | 一种治疗乳腺癌的中药制剂 |
| CN103349764A (zh) * | 2013-07-09 | 2013-10-16 | 宋克垣 | 一种治疗乳腺癌的药物及其制备方法 |
-
2021
- 2021-12-21 CN CN202111570634.7A patent/CN114028531B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114028531A (zh) | 2022-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101947284B (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
| CN107789484B (zh) | 一种治疗月经不调的中药组合物及其制备方法 | |
| CN101711848B (zh) | 一种辅助治疗肿瘤的中药组合物 | |
| CN103623280B (zh) | 一种治疗心脑血管疾病的中药制剂 | |
| CN104815166A (zh) | 一种治疗糖尿病的中药组合物及其制备和应用 | |
| CN114028531B (zh) | 一种治疗乳腺癌的药物及其制备方法和应用 | |
| CN114748603B (zh) | 一种防治新冠病毒肺炎变异或复阳的药物组合物和应用 | |
| CN115837065A (zh) | 一种中药组合物及其用途 | |
| CN101474388B (zh) | 一种改进的仙蟾片药物处方及其制备方法 | |
| CN102743703A (zh) | 一种治疗颈椎病的药物及其制备方法 | |
| CN105434739A (zh) | 一种治疗霰粒肿的中药组合物及其制备方法 | |
| CN106822733B (zh) | 一种治疗慢性萎缩性胃炎癌前病变的膏剂及制备方法 | |
| CN110624079A (zh) | 一种用于改善癌因性疲乏和肿瘤放化疗反应的中药组合物 | |
| CN105902867B (zh) | 一种降三高的植物药组合物及其制备方法 | |
| CN104622995A (zh) | 一种治疗慢性浅表性胃炎的药物组合物及其制备方法 | |
| CN111870650A (zh) | 一种侗族药酒及其制备方法 | |
| CN108853340A (zh) | 一种滋养肝肾的中药及其制备方法 | |
| CN108079113A (zh) | 一种治疗产后血虚的药物组合物及其制备方法 | |
| CN107362296B (zh) | 治疗皮肤良性肿瘤的药物及其制备方法 | |
| CN101530589B (zh) | 一种治疗癌症的中药制剂 | |
| CN108721572B (zh) | 一种治疗肝癌及肝硬化的中药组合物 | |
| CN101693096A (zh) | 一种治疗肝癌的药物及其制备方法 | |
| CN108144026B (zh) | 一种用于骨关节炎的药物组合物 | |
| CN116115714A (zh) | 一种抗肿瘤中药组合物及其制备方法和应用 | |
| CN104547945A (zh) | 一种治疗淋巴结核的中药制剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |